pressure and lipids can relieve DN symptoms, current treatments are insufficient to efficiently prevent the progression of DN from stage 3 to stage 4. 5 Hence, there is an urgent need for new strategies that interrupt mechanisms underlying the progression of stage 3 DN induced by hyperglycaemia.
Hyperglycaemia-induced inflammation pathways play central roles in the progression of stage 3 DN. [6] [7] [8] The major clinical and recognized hallmark of stage 3 DN is elevated albuminuria secretion (20 μg/min < urine albumin excretion rate < 200 μg/min). 9 The classical histological features of stage 3 DN include mesangial expansion, glomerular basement membrane thickening, tubule-interstitial fibrosis and lymphocytes influx. 10 Recent findings suggest that the basic underlying mechanisms of DN involve high-glucose (HG) induced production of inflammatory mediators in glomerular and tubular cells, which triggers lymphocytes infiltration, renal cell proliferation and extracellular matrix expansion. 11, 12 Thus, there is a obvious need for new strategies that simultaneously ameliorate systemic metabolism disorder and renal micro-inflammation to slow the decline of renal function in DN.
Protein tyrosine phosphatase non-receptor type 2 (PTPN2) might be the key regulator that controls metabolism and micro-inflammation. [13] [14] [15] PTPN2, one of 17 intracellular and non-receptor PTPs, was originally cloned from a human T-cell cDNA library. 16 It is ubiquitously expressed (eg intestinal and renal epithelium, fibroblasts, hepatocytes). 17 It has been indicated that PTPN2 is indispensable for maintaining metabolic homeostasis, 13 and liver-specific PTPN2 deficiency promotes hepatic steatosis, obesity and insulin resistance (IR). 15 Evidence is emerging for the involvement of PTPN2 in the onset and progression of inflammatory diseases, such as Crohn's disease, T1DM and rheumatoid arthritis. 14, 16, 18, 19 Although these results suggest the important role of PTPN2 in metabolic diseases and inflammation, it remains unknown whether PTPN2 contributes to the progression of DN. HG-induced STAT activation contributes to the expression of pro-inflammatory and pro-fibrotic factors in glomerular and tubular cells and infiltration by circulating inflammatory cells, which amplifies and perpetuates the inflammatory process in the kidney, finally resulting in the development and progression of DN. [20] [21] [22] PTPN2 is the key negative regulator that controls the magnitude and duration of STAT signalling through several mechanisms, including kinase inhibition and STAT binding. 23, 24 Thus, PTPN2 may suppress the expression of pro-inflammatory cytokines via inhibiting STAT signalling pathway and thus ameliorate renal injury and fibrosis in DN.
In the present study, we constructed an early DN ApoE -/-mouse model. We aimed to explore whether PTPN2 gene therapy could improve DN by regulating systemic metabolic disorders and inhibiting local inflammation in kidney.
| MATERIAL S AND ME THODS

| Reagents and antibodies
Dulbecco's modified Eagle's medium (DMEM) and foetal bovine serum (FBS) were from Gibco (Grand Island, NY 
| In vitro studies
Both mouse murine mesangial cells (MC) and tubuloepithelial cells (MCT)
were purchased from were ATCC, and authenticated by STR profiling and tested for mycoplasma contamination by GENEWIZ. MC and MCT were cultured in low glucose (5.5 mmol/L D-glucose) DMEM media supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin and 10% 
| Diabetic model and in vivo experiments
Four-week-old male ApoE -/-mice were randomly assigned to a control group and diabetic group. The control group was fed a normal diet; the diabetic groups received a high-fat (HF) diet (34 
| Production of adenoviral vector
The recombinant pAdxsi adenovirus constitutively expressing PTPN2 was constructed using the pAdxsi Adenoviral System (Hanbio Biotechnology Co., Ltd., Shanghai, China). The PTPN2 cDNAs from mouse were inserted into pShuttle-CMV-EGFP vector. The pAdxsi vector adenovirus was used as the control vehicle virus. After amplification, viruses were purified, titered and stored at −80°C until used.
| Blood and urine examination
At the end of the experiment, the mice were fasted overnight and killed by an overdose of pentobarbital. Fasting blood glucose, total cholesterol (Chol), LDL-cholesterol (LDL-chol), HDL-cholesterol (HDL-chol), triglyceride (TG) and non-estesterified fatty acid (NEFA)
were measured. Different serum enzymes were estimated following standard methods namely aspartate transaminase (AST) and alanine transaminase (ALT). 26 Blood urea nitrogen (BUN) and creatinine in the plasma and urinary albumin were estimated using standard kits (Nanjing Jiancheng, Nanjing, China).
| Histology and immunohistochemistry
Kidney samples were fixed with 4% paraformaldehyde overnight and embedded in paraffin. Paraffin-embedded kidney sections (5-μm thick) 
| Immunofluorescence staining and microscopy
The cryosections were blocked with 5% BSA blocking buffer and stained with antibodies against PTPN2, VEGF and CD31 at 4°C
overnight. The stained sections were washed with PBS and further incubated with Alexa Fluor 488 secondary antibodies (Proteintech Group Inc, Chicago, IL) followed by nuclear counterstain (4′,6-diamidino-2-phenylindole). The samples were washed three times in PBS, and examined under a laser scanning confocal microscope (LSM710;
Carl Zeiss, Germany), and data were analysed using Image-Pro Plus TA B L E 2 Renal scores of non-diabetic and diabetic mice
| Western blot analyses
Total proteins from cells and tissues were separated in a 10% SDS-PAGE and transferred onto PVDF membranes. After blocking in 5% skim milk for 60 minutes, the membranes were incubated with primary antibodies for PTPN2, P-STAT1, STAT1, P-STAT3, STAT3, Arg I, Arg II, Col I, Col IV, Fn, TGF-β, PAI-1, MCP-1, TNF-α, IL-6, ICAM-1 and VEGF, followed by anti-IgG horseradish peroxidase-conjugated secondary antibody. The membrane bands were visualized by use of chemiluminescence (Millipore) and quantified by densitometry.
| Statistical analyses
Values are presented as mean ± SEM. Results were compared by one-way ANOVA. P < 0.05 was considered statistically significant. 
| PTPN2 gene therapy protected from diabetesassociated renal injury in ApoE -/-mice
We then investigated the effects of PTPN2 gene therapy on renal dysfunctions in mice with established experimental DN. As shown in Figure 2A ,B, PTPN2 gene therapy markedly reduced serum levels of creatinine and BUN in diabetic mice, indicating largely improved renal lesions after PTPN2 gene transfer. Moreover, the proteinuria level, a clinical predictor of renal injury in DN, was significantly ameliorated in diabetic mice after PTPN2 overexpression ( Figure 2C ). In addition, PTPN2 gene therapy resulted in significant decrease of kidney/body weight ratio (Table 1) .
Histological examination of HE and PAS-stained kidney samples showed that PTPN2 improved several morphologic changes within the glomerulus (hypercellularity, mesangial matrix expansion and capillary dilation), tubules (atrophy and degeneration) and interstitium (fibrosis and inflammatory infiltrate) of diabetic mice ( Figure 2D , Table 2 ). Digital quantification further indicated that PTPN2 gene therapy reduced glomerular size and PAS + -mesangial area ( Figure 2E ). Collectively, these data suggested that PTPN2 overexpression effectively attenuated renal injury in experimental DN.
| PTPN2 gene therapy improved insulin resistance and metabolic disorders in diabetic mice
It has been well acknowledged that DN is an inflammatory disease triggered by disordered metabolism. Thus, we investigated whether PTPN2 could regulate metabolism in mice with established experimental DN. As shown in Figure 3A ,B, PTPN2 gene therapy markedly improved frank hyperglycaemia, glucose tolerance and IR, indicating that better blood glucose control in diabetic mice by PTPN2 overexpression ( Figure 3A ,B). It has been universally recognized that liver plays a central role in metabolic balance with numerous functions.
Thus, we then explored whether liver lesions induced by diabetes were improved after PTPN2 overexpression. As shown in Figure 3C , the increased serum levels of ALT and AST were markedly reduced in diabetic mice after PTPN2 overexpression. In addition, PTPN2 overexpression significantly improved hepatomegaly in diabetic mice, as assessed by the liver index ( Figure 3D ). Meanwhile, liver lesions induced by diabetes such as hepatic vacuolization, necrosis and fibrosis were significantly improved after PTPN2 gene transfer, as indicated by pathological examination ( Figure 3E,F) . Furthermore, PTPN2 gene therapy markedly ameliorated disordered metabolism in diabetic mice as demonstrated by serum levels of triglyceride, total cholesterol and LDL-cholesterol that were decreased to those of control mice (Table 1 ). These results indicated that PTPN2 gene transfer ameliorated hyperglycaemia and disordered metabolism, which exert a protective effect on DN.
| PTPN2 gene therapy reduced diabetesinduced renal inflammation
The induction of diabetes was associated with the recruitment, retention and activation of leucocytes in the mouse kidney, as indicated by increased expression of leucocyte markers and pro-inflammatory genes ( Figure 4A ,C). PTPN2-treated mice showed a significant decrease in the number of infiltrating CD3 + T lymphocytes and F4/80 + macrophages ( Figure 4A,B) . Moreover, PTPN2 gene therapy (CD206 and Arg I) the predominant macrophage marker in the PTPN2 overexpression group (Figure 4A,E) . In summary, these results indicated that PTPN2 gene therapy effectively prevented diabetes-induced renal inflammation in DN.
| PTPN2 gene therapy decreased fibrosis in diabetic mice
Since 
| PTPN2 gene therapy inhibited STAT activation in diabetic kidneys
Mounting evidence has demonstrated that the STAT signalling pathway modulates a broad range of mediators participated in pro-inflammatory and pro-fibrotic factors and is an important mechanism through which hyperglycaemia contribute to DN. Thus, we explored whether PTPN2 could modulate STAT activation in DN. As shown in Figure 6A ,E, the protein expression of PTPN2 in kidney was markedly increased in the PTPN2 overexpression 
| Hyperglycaemia caused PTPN2 downregulation and STAT activation in renal cells
To corroborate the experimental model we assessed, in vitro, the Figure 8G,I ). In addition, the tyrosine phosphorylation of STAT1 and STAT3 was induced by HG, peaking at 24 hours ( Figure 8G,I ). These findings indicated that hyperglycaemic treatment caused PTPN2 down-regulation and STAT activation in renal cells.
| PTPN2 inhibited HG-induced STAT activation, STAT-dependent genes and cell proliferation
To To evaluate the functional consequences of inflammatory gene reduction, we next examined the effect of PTPN2 on cell proliferation-important processes involved in renal damage during DN. As shown in Figure 9L , the proliferative effect of HG on MC and MCT was prevented by PTPN2 overexpression.
These data suggested that PTPN2 could inhibit HG-induced STAT activation, STAT-dependent genes and cell proliferation in murine mesangial cells and tubuloepithelial cells.
| D ISCUSS I ON
In this study, we found that diabetic mice developed albuminuria, PTPN2 stands at the crossroad of multiple signalling mechanisms and has emerged as an interesting therapeutic target with regulation of metabolism and micro-inflammation. 13 21, 22, 32, 33 Previous studies have demonstrated that suppression of PTPN2 expression contributing to sustained STAT activation leads to the development and progression of chronic inflammatory diseases. 14, 29 Consistent with previous data, we found that PTPN2 overexpression could inhibit STAT1/3 activation in vitro and in vivo.
Therefore, we proposed that PTPN2 gene therapy may reduce the expression of pro-inflammatory and pro-fibrotic cytokines via inhibiting STAT1/3 signalling pathway and thus improve renal lesions and fibrosis in DN.
Moreover, our results on the anti-angiogenic effects of PTPN2 also interpreted the amelioration of renal injury in diabetic mice.
VEGF-induced angiogenesis contributes to the pathogenesis of Consistent with these results, we found that angiogenesis using CD31 as marker was significantly increased in kidney in the diabetic group. PTPN2 gene therapy significantly suppressed VEGF expression and angiogenesis in diabetic mice. The immature structure and function of neo-vascular increase glomerular filtration barrier and elevate permeability, resulting in 24-hour proteinuria, glomerular sclerosis, interstitial fibrosis by promoting extracellular matrix deposition. 34, 39 In summary, PTPN2, as a critical regulator for metabolic disorder and inflammation, participated in DN. The kidney protective roles with PTPN2 overexpression indicate a potential role for PTPN2 analogue in treating DN.
